118 related articles for article (PubMed ID: 33060154)
1. mTORC1 hyperactivation in lymphangioleiomyomatosis leads to
Tang Y; Kwiatkowski DJ; Henske EP
Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 33060154
[TBL] [Abstract][Full Text] [Related]
2. Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study.
Parit R; Jayavel S
Eur J Pharmacol; 2021 Apr; 896():173899. PubMed ID: 33508281
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases.
Sharma RK; Li J; Krishnan S; Richards EM; Raizada MK; Mohandas R
Clin Sci (Lond); 2021 Jan; 135(1):1-17. PubMed ID: 33399851
[TBL] [Abstract][Full Text] [Related]
4. Expression of the SARS-CoV-2 Receptor ACE2 and Proinflammatory Cytokines Induced by the Periodontopathic Bacterium
Takahashi Y; Watanabe N; Kamio N; Yokoe S; Suzuki R; Sato S; Iinuma T; Imai K
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572938
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Evolution of ACE2 and IL-6 Genes: Non-Canonical Interferon-Stimulated Genes Correlate to COVID-19 Susceptibility in Vertebrates.
Sang ER; Tian Y; Miller LC; Sang Y
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33503821
[TBL] [Abstract][Full Text] [Related]
6. A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice.
Wang Y; Takeshita H; Yamamoto K; Huang Y; Wang C; Nakajima T; Nozato Y; Fujimoto T; Yokoyama S; Hongyo K; Nakagami F; Akasaka H; Takami Y; Takeya Y; Sugimoto K; Rakugi H
FASEB J; 2021 Mar; 35(3):e21419. PubMed ID: 33566370
[TBL] [Abstract][Full Text] [Related]
7. ACE2: from protection of liver disease to propagation of COVID-19.
Warner FJ; Rajapaksha H; Shackel N; Herath CB
Clin Sci (Lond); 2020 Dec; 134(23):3137-3158. PubMed ID: 33284956
[TBL] [Abstract][Full Text] [Related]
8. ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Serine Protease 2) Expression and Localization of SARS-CoV-2 Infection in the Human Heart.
Sakamoto A; Kawakami R; Kawai K; Gianatti A; Pellegrini D; Kutys R; Guo L; Mori M; Cornelissen A; Sato Y; Bellasi A; Faggi L; Hong C; Romero M; Guagliumi G; Virmani R; Finn AV
Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):542-544. PubMed ID: 33086866
[No Abstract] [Full Text] [Related]
9. Anti-TNF-α agents Modulate SARS-CoV-2 Receptors and Increase the Risk of Infection Through Notch-1 Signaling.
Keewan E; Beg S; Naser SA
Front Immunol; 2021; 12():641295. PubMed ID: 34025650
[TBL] [Abstract][Full Text] [Related]
10. ACE2 and energy metabolism: the connection between COVID-19 and chronic metabolic disorders.
Cao X; Song LN; Yang JK
Clin Sci (Lond); 2021 Feb; 135(3):535-554. PubMed ID: 33533405
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of ACE2 and TMPRSS2 by particulate matter and idiopathic pulmonary fibrosis: a potential role in severe COVID-19.
Li HH; Liu CC; Hsu TW; Lin JH; Hsu JW; Li AF; Yeh YC; Hung SC; Hsu HS
Part Fibre Toxicol; 2021 Mar; 18(1):11. PubMed ID: 33706759
[TBL] [Abstract][Full Text] [Related]
12. Role of angiotensin-converting enzyme 2 in neurodegenerative diseases during the COVID-19 pandemic.
Li Z; Xu X; Yang M; Feng J; Liu C; Yang C
Aging (Albany NY); 2020 Nov; 12(23):24453-24461. PubMed ID: 33197881
[TBL] [Abstract][Full Text] [Related]
13. High expression of ACE2 in the human lung leads to the release of IL6 by suppressing cellular immunity: IL6 plays a key role in COVID-19.
Bao Z; Wang LJ; He K; Lin X; Yu T; Li J; Gong J; Xiang G
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):527-540. PubMed ID: 33506945
[TBL] [Abstract][Full Text] [Related]
14. Population-Specific
Hashizume M; Gonzalez G; Ono C; Takashima A; Iwasaki M
Viruses; 2021 Jan; 13(1):. PubMed ID: 33418950
[TBL] [Abstract][Full Text] [Related]
15. Using Genetics To Dissect SARS-CoV-2 Infection.
Brest P; Mograbi B; Hofman P; Milano G
Trends Genet; 2021 Mar; 37(3):203-204. PubMed ID: 33309104
[TBL] [Abstract][Full Text] [Related]
16. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation of ACE2, the receptor of the SARS-CoV-2 virus
Beacon TH; Delcuve GP; Davie JR
Genome; 2021 Apr; 64(4):386-399. PubMed ID: 33086021
[TBL] [Abstract][Full Text] [Related]
18. ACE2 and SARS-CoV-2: Tissue or Plasma, Good or Bad?
Wenzel UO; Kintscher U
Am J Hypertens; 2021 Apr; 34(3):274-277. PubMed ID: 33151267
[No Abstract] [Full Text] [Related]
19. ACE2 role in SARS-CoV-2 infectivity and Covid-19 severity.
Azizan E; Brown M
Malays J Pathol; 2020 Dec; 42(3):363-367. PubMed ID: 33361716
[TBL] [Abstract][Full Text] [Related]
20. ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19.
Yamamoto K; Takeshita H; Rakugi H
Clin Sci (Lond); 2020 Nov; 134(22):3047-3062. PubMed ID: 33231620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
